TNF and rheumatoid arthritis: In addition, targeting SMs by TNF-α inhibitors (98), Bruton’s tyrosine kinase (BTK) inhibitors (99), and sex hormone modulators (100), and clearance of overexpressed IgG high-affinity receptors (FcγRI) (81) can be useful in the treatment of RA.